Trial Search Results
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: National Institutes of Health (NIH)
Stanford Investigator(s):
Intervention(s):
- Procedure: ablative allogeneic hematopoietic cell transplantation
Phase:
Phase 2
Eligibility
Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma
Age: >18 and <61 years of age
Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum
transaminases >2.5X normal values
Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min
Diseases other than non-Hodgkin's lymphoma
Prior bone marrow transplant procedure
Severe psychological or medical illness
Ages Eligible for Study
18 Years - 61 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822